Personal finance

Biden renews call to let Medicare negotiate drug prices, an effort that has stalled in Congress

FatCamera | E+ | Getty Images

President Joe Biden apparently hasn’t given up on a proposal aimed at reducing prescription drug prices, especially for retirees.

In his State of the Union address Tuesday night, Biden called for capping insulin prices at $35 a month for all Americans, as well as allowing Medicare to negotiate prices with drug manufacturers — something that currently isn’t permitted.

“I know we have great disagreements on this floor with this — let’s let Medicare negotiate the price of prescription drugs,” Biden said in his speech to congressional lawmakers.

More from Personal Finance:
Nearing retirement? Be sure to manage this big risk
Tips for saving at the pump as gas prices climb
3 last-minute moves to slash your 2021 tax bill

Both the insulin price cap and Medicare negotiation provisions were included in last year’s proposed $1.75 trillion Build Back Better Act, which was a reflection of Biden’s goal of strengthening the social safety net and tackling climate change.

However, the measure fell apart in the Senate late last year after clearing the House in November. In that bill, price negotiations with drug makers would have started in 2025 with up to 10 drugs year. That number would have reached 20 by 2028.

The bill also included a provision to cap beneficiaries’ out-of-pocket spending for Medicare’s drug benefit (Part D) at $2,000 annually beginning in 2024 with yearly adjustments.

For some of Medicare’s 63.3 million beneficiaries — the majority of whom are age 65 or older  — limiting out-of-pocket drug spending could mean saving thousands of dollars per year because there currently is no cap.

Roughly 1.2 million enrollees spent more than $2,000 each on drugs delivered through Part D in 2019, according to research from the Kaiser Family Foundation.

It’s uncertain whether lawmakers will revive efforts to pass Biden’s domestic agenda and whether lowering drug prices will be included.

Products You May Like

Articles You May Like

Top Wall Street analysts find these stocks compelling
Before you enroll in Medicare, what to know about new rules that eliminate coverage gaps
Alphabet misses on earnings and revenue as YouTube falls short
‘Phishing-as-a-service’ kits are driving an uptick in theft: What you can learn from one business owner’s story
One of Jeff Bezos’ secrets to success: The boss should always talk last in meetings